DSpace Repository

Intravenous Fosphenytoin as Rescue Treatment in Trigeminal Neuralgia Crisis (P5.10-013)

Show simple item record

dc.contributor.author Schnell, Susana
dc.contributor.author Marrodán, Mariano
dc.contributor.author Goicochea, María Teresa
dc.contributor.author Bonamico, Lucas
dc.date.accessioned 2020-12-22T12:14:25Z
dc.date.available 2020-12-22T12:14:25Z
dc.date.issued 2019-05-09
dc.identifier.citation Schnell, S., Marrodan, M., Goicochea, M., Bonamico. Intravenous Fosphenytoin as Rescue Treatment in Trigeminal Neuralgia Crisis (P5.10-013). Neurology. 2019;92(15 Supplement). P5.10-013 en_US
dc.identifier.uri https://n.neurology.org/content/92/15_Supplement/P5.10-013.abstract
dc.identifier.uri https://repositorio.fleni.org.ar/handle/123456789/279
dc.description.abstract Objective: The aim of this study is to analyze the response to intravenous (iv) fosphenytoin in Trigeminal Neuralgia (TN) crisis in order to gather evidence for its use in daily neurological practice. Background: TN is a common cause of facial pain. Its treatment relies on preventive therapy with either carbamazepine or oxcarbazepine. During a severe pain episode patients are unable to eat, drink or continue with oral medication, requiring inhospital treatment. There is scarce evidence based support for iv medications for TN, hindering the management of these situations. Design/Methods: A retrospective review was carried out from clinical records of patients with TN crisis, who attended the emergency department in a referral tertiary neurological center in Buenos Aires, Argentina, and received iv fosphenytoin as analgesic strategy; having being followed-up for at least one month afterwards. Demographic features, magnetic resonance imaging (MRI) and emergency room pharmacological management were analyzed. Patients were diagnosed of TN and classified according to ICHD-3 diagnostic criteria. Results: Thirty-nine patients with TN were included, over 50% received iv fosphenytoin applications more than once (separated by at least 24hs), reaching a total of 73 infusions. Immediate pain relief was achieved in 85% of cases. Furthermore, alongside with preventive therapy adjustments, individualized attendance to the emergency service decreased after each infusion in 58% episodes. Adverse effects were seen in 26% of patients, being dizzines and nausea the most frequent (n=10 and n=3, respectively). Conclusions: According to our results, iv fosphenytoin may be a safe and useful strategy for TN crisis, considering the lack of treatment choices for these situations. Nonetheless a prospective placebo controlled study is needed to make a valid statement. en_US
dc.language.iso eng en_US
dc.publisher AAN en_US
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Fosphenytoin en_US
dc.subject Fosfenitoína en_US
dc.subject Trigeminal Neuralgia en_US
dc.subject Neuralgia del Trigémino en_US
dc.title Intravenous Fosphenytoin as Rescue Treatment in Trigeminal Neuralgia Crisis (P5.10-013) en_US
dc.type info:eu-repo/semantics/publishedVersion
dc.type info:eu-repo/semantics/other en_US
dc.description.fil Fil: Schnell, Susana. Fleni. Departamento de Neurología; Argentina.
dc.description.fil Fil: Marrodán, Mariano. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.
dc.description.fil Fil: Goicochea, María Teresa. Fleni. Departamento de Neurología. Clínica del Dolor. Clínica de Cefaleas; Argentina.
dc.description.fil Fil: Bonamico, Lucas. Fleni. Departamento de Neurología. Clínica del Dolor. Clínica de Cefaleas; Argentina.
dc.relation.ispartofVOLUME 92
dc.relation.ispartofNUMBER 15
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Hagerstown
dc.relation.ispartofTITLE Neurology
dc.relation.ispartofISSN 1526-632X
dc.type.snrd info:ar-repo/semantics/artículo es_ES

Files in this item

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess

Search DSpace


My Account